Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."Immunotherapy in Non-Small Cell Lung Cancer
Advertisement
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.